Testosterone effective treatment for low libido in postmenopausal women
An interim analysis of a breast cancer prevention study using exemestane (Aromasin) finds an “acceptable” level of bone loss. The ongoing phase II study details reported, by Jennifer Eng-Wong, MD, a breast cancer specialist at Georgetown’s Lombardi Comprehensive Cancer Center at the San Antonio Breast Cancer Symposium, examines the use of exemestane in postmenopausal women
Full Post: Planned safety analysis of a breast cancer prevention study reveals encouraging news for Exemestane
An international study showed testosterone, when used with no other hormone therapy, is an effective treatment for low libido in postmenopausal women.
More than 800 women from 65 centers in the United States, Canada, Australia, the United Kingdom and Sweden participated in the study, the first to show that testosterone administered by a skin patch can boost sex drive in postmenopausal women.
Previous studies have shown testosterone treatment for low libido is beneficial for women undergoing estrogen therapy. However, this study shows testosterone by itself could be a good alternative for women who do not want to take estrogen.
Glenn Braunstein, M.D., chairman of the Department of Medicine at Cedars-Sinai Medical Center, is a primary investigator of the study and a co-author of an article in the New England Journal of Medicine. He is an expert in endocrinology, diabetes and metabolism, with a major research focus on androgen physiology in women and androgen treatment of women.
The study will be published in the Nov. 6 issue of the New England Journal of Medicine . Dr. Braunstein is available for interviews by appointment.
The study was supported by funding from Proctor & Gamble Pharmaceuticals USA. Dr. Braunstein has previously served as a paid consultant for Proctor & Gamble and he reviewed this study data on behalf of the company.
According to research by an international team of scientists testosterone could recharge the sex lives of older women. New research has found that testosterone patches can significantly increase the sex drive of postmenopausal women not on hormone replacement therapy. The study, led by Professor Susan Davis from Monash University is the first research which has
Full Post: Testosterone patches charge up older women’s sex
Introduced in the 1960s, oral contraceptives have been used by about 80 percent of women in the United States at some point in their lives. For women without pre-existing risks for heart disease, the early formulations were generally safe, and the newer ones appear to be even safer, but all the risks and benefits are
Full Post: Oral contraceptives may be safe, but information gaps remain
The combination of estrogen plus progestin, which women stopped taking in droves following the news that it may increase their risk of breast cancer, may decrease their risk of colorectal cancer, according to a report published in the January issue of Cancer Epidemiology, Biomarkers and Prevention, a journal of the American Association for Cancer Research.
Full Post: Estrogen plus progestin therapy may decrease risk of colorectal cancer
The January issue of European Urology, the official journal of the European Association of Urology published by Elsevier, will feature new recommendations on late-onset hypogonadism (LOH), recently formulated by major scientific organizations. LOH is a clinical and biochemical syndrome associated with advancing age and characterized by typical symptoms and a deficiency in serum testosterone levels.
Full Post: New recommendations on late-onset hypogonadism
The hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years. Now, researchers at Johns Hopkins have discovered critical differences in the hormone receptors on prostate cancer cells in patients who no longer respond to this therapy. The findings,
Full Post: Why prostate cancer patients fail hormone deprivation therapy